Hinova Pharmaceuticals Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING3
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HC-1119 NCT03851640 |
P3 | Recruiting | MCRPC | 417 | 2025-09 |
| HP568 NCT06757335 |
P1/2 | Not yet recruiting | Breast Cancer | 204 | 2026-01-31 |
| HP518 - Dose Escalation NCT06155084 |
P1/2 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 84 | 2026-03 (-4 mo) |
| NASH/MASH NCT07308548 |
P2 | Recruiting | NAFLD (Non-alcoholic Fatty Liver Disease) | 80 | 2026-08-13 |
| Deutenzalutamide Soft Capsules + ADT NCT07875881 |
P3 | Not yet recruiting | High Risk Biochemical Recurrence (BCR); Deutenzalutamide Soft Capsules | 1044 | 2029-12-31 |